The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | CLL space: current treatment options and next steps
Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, reflects on the treatment landscape for chronic lymphocytic leukemia (CLL) highlighting the efficacy of BTK inhibitors and BCL-2 inhibitors as standard of care (SOC) treatments for patients with CLL. Prof. Ghia also discusses the next steps in this disease setting including the use of measurable residual disease (MRD) status to influence treatment decisions in the clinic. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
